dusigitumab (MEDI-573) / AstraZeneca - LARVOL DELTA

Integrated analysis and clinical correlation analysis of hub genes, immune infiltration, and potential therapeutic agents related to lupus nephritis. (PubMed, Lupus) - "We analyzed the transcriptomic signature of LN along with the landscape of the immune cell. FOS and IGF1 are promising biomarkers for diagnosing and evaluating the progression of LN. The drug-gene interaction analyses provide a list of candidate drugs for the precise treatment of LN."

Journal • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus • IGF1

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer (clinicaltrials.gov) - P1b/2; N=188; Active, not recruiting; Sponsor: MedImmune LLC; Trial completion date: Jun 2018 ➔ Jun 2020

Trial completion date • Biosimilar • HER2 Breast Cancer

Correction: MEDI-573, Alone or in Combination with Mammalian Target of Rapamycin Inhibitors, Targets the Insulin-like Growth Factor Pathway in Sarcomas. (PubMed) - "No abstract available "

Journal • Biosimilar • Oncology • Sarcoma

Safety, pharmacokinetics, and antitumor activity of MEDI-573, an investigational monoclonal antibody that targets IGF-I and IGF-II, in adult patients with advanced solid tumors (ASCO 2012) - Presentation time: Mon, Jun 4; 8:00 AM - 12:00 PM; Anticipated presentation at ASCO 2012

Anticipated data presentation • Oncology

AstraZeneca: ASCO 2014 Meeting (AstraZeneca) - Anticipated regulatory submission for metastatic breast cancer after 2017

Anticipated regulatory • Breast Cancer • Oncology

A dose-escalation study to evaluate the safety, tolerability, and antitumor activity of MEDI-573 in subjects with advanced solid tumors (clinicaltrials.gov) - P1, N=43; Recruiting → Active, not recruiting;

Enrollment closed • Oncology

MEDI-573 in combination with SOC in unresectable or metastatic HCC (MEDI-573-1028) (clinicaltrials.gov) - P1, N=9 -> 6; Sponsor: MedImmune LLC; Recruiting -> Active, not recruiting; Completion date: Apr 2014 -> May 2013.

Enrollment closed • Trial completion date • Hepatocellular Cancer • Oncology

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer (clinicaltrials.gov) - P1b/2; N=188; Completed; Sponsor: MedImmune LLC; Active, not recruiting ➔ Completed; Trial completion date: Jun 2020 ➔ Jun 2019; Trial primary completion date: May 2017 ➔ Jun 2019

Clinical • Combination therapy • Trial completion • Trial completion date • Trial primary completion date